LACTB2

Across TCGA pan-cancer cohorts, LACTB2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LACTB2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LACTB2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LACTB2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where LACTB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.670	0.409	<.001	86	view →
CCRCC	DFS	Tertile	IV	0.150	0.794	.024	6	view →
LSCC	DFS	Quartile	All	0.273	0.831	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LACTB2–PDAC (OS)

Open the PDAC breakdown →